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Abstract
Background: The vitamin A metabolite, retinoic acid (RA), plays important roles in the regulation of lymphocyte properties.
Dendritic cells in gut-related lymphoid organs can produce RA, thereby imprinting gut-homing specificity on T cells and
enhancing transforming growth factor (TGF)-b-dependent induction of Foxp3
+ regulatory T cells upon antigen presentation.
In general, RA concentrations in cells and tissues are regulated by its degradation as well. However, it remained unclear if T
cells could actively catabolize RA.
Methodology/Principal Findings: We assessed the expression of known RA-catabolizing enzymes in T cells from mouse
lymphoid tissues. Antigen-experienced CD44
+ T cells in gut-related lymphoid organs selectively expressed Cyp26b1,a
member of the cytochrome P450 family 26. However, T cells in the spleen or skin-draining lymph nodes did not significantly
express Cyp26b1. Accordingly, physiological levels of RA (1–10 nM) could induce Cyp26b1 expression in naı ¨ve T cells upon
activation in vitro, but could not do so in the presence of TGF-b. Overexpression of Cyp26b1 significantly suppressed the RA
effect to induce expression of the gut-homing receptor CCR9 on T cells. On the other hand, knocking down Cyp26b1 gene
expression with small interfering RNA or inhibiting CYP26 enzymatic activity led to enhancement of the RA-induced CCR9
expression.
Conclusions/Significance: Our data demonstrate a role for CYP26B1 in regulating RA-dependent signals in activated T cells
but not during TGF-b-dependent differentiation to Foxp3
+ regulatory T cells. Aberrant expression of CYP26B1 may disturb T
cell trafficking and differentiation in the gut and its related lymphoid organs.
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Introduction
The vitamin A metabolite, retinoic acid (RA), plays critical roles
in many life processes including immune responses. Among the
roles, the regulation of lymphocyte trafficking is essential for the
gut immunity [1,2]. We have previously found that RA induces
the expression of the gut-homing receptors, a4b7 integrin and
chemokine receptor CCR9, on T and B cells upon activation, and
imprints them with gut-homing specificity [1,3]. Activation of
naı ¨ve T cells is dependent on antigen presentation by dendritic
cells (DCs) in lymphoid tissues. DCs in gut-related lymphoid
organs can produce RA by expressing the key RA-synthesizing
enzyme, retinaldehyde dehydrogenase (RALDH), and imprint gut
tropism on T cells during antigen presentation [1,4,5]. It has been
also found that these DCs enhance the transforming growth factor
(TGF)- b-dependent differentiation of naı ¨ve CD4
+ T cells to
Foxp3
+ inducible regulatory T cells (iTreg) and suppress the TGF-
b/IL-6-dependent differentiation of proinflammatory Th17 cells
[6–11]. However, it remains unclear how RA is catabolized in T
cells to prevent excessive RA stimulation.
It is known that RA-mediated signaling is regulated during the
embryonic morphogenesis through coordinated regulation of RA
synthesis and catabolism [12]. Several cytochrome P450 (CYP)
enzymes are known to catabolize RA via several routes leading to a
variety of polar catabolites; the immediate products include 4-
hydroxy-RA, 4-oxo-RA, 18-hydroxy-RA and 5,6-epoxy-RA [13].
The predominant pathway is oxidation at the 4-position of the
cyclohexenyl ring to form 4-hydroxy-RA [14]. Among the CYP
enzymes, the CYP26 family (CYP26A1, CYP26B1 and CYP26C1)
is likely to be responsible for much of the RA-inducible RA
metabolism.EachCyp26genehasadistinctpatternoforgan-specific
expression during early embryogenesis [15–17]. RA levels decrease
in the regions where Cyp26 genes are expressed, and mice lacking
either Cyp26a1 or Cyp26b1 die in utero or immediately after birth and
exhibit abnormalities consistent with those seen in RA teratogenesis
[18–20]. Thus, the coordinated regulation of the RALDH activity
and the CYP26 activity determines the RA stimulation level.
In the present study, we detected the expression of Cyp26b1 but
not Cyp26a1 or Cyp26c1 in effector/memory populations of T cells
from gut-related lymphoid organs but not those from skin-draining
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expression of Cyp26b1 but not Cyp26a1 or Cyp26c1 in T cells upon
activation. Forced changes in the Cyp26b1 expression affected the
Ccr9 expression. The RA-induced Cyp26b1 expression was,
however, markedly inhibited by TGF-b. The combination of
RA and TGF-b induces the differentiation of CD4
+ naı ¨ve T cells
to Foxp3
+ inducible regulatory T cells (iTreg) upon activation.
Thus, CYP26B1 may not disturb RA signals in developing Foxp3
+
iTreg.
Results
Expression of Cyp26b1 in CD4
+ and CD8
+ T cells in gut-
related lymphoid organs
CD4
+ T cells and CD8
+ T cells obtained from the gut-related
lymphoid organs, mesenteric lymph nodes (MLN) and Payer’s
patches, expressed Cyp26b1 but not Cyp26a1 or Cyp26c1 (Fig. 1A).
Among CD4
+ T cells in MLN, CD44
+ effector/memory T cells
but not CD44
-CD62L
high naı ¨ve T cells expressed Cyp26b1
(Fig. 1B). However, T cells from the spleen or skin-draining
peripheral lymph nodes (PLN) did not significantly express any of
the Cyp26 genes (Fig. 1A, 1B and data not shown).
RA induces Cyp26b1 expression in T cells upon activation
As RA is consistently provided by DCs and some other cells in
the gut-related lymphoid organs [1,21], we examined if RA
induced Cyp26b1 expression in T cells. Indeed, the expression of
Cyp26b1 but not Cyp26a1 or Cyp26c1 was induced in naı ¨ve CD4
+ T
cells upon activation in the presence of the major physiologic RA,
all-trans-RA (AtRA) (Fig. 2A). It has been previously demonstrated
that the CYP enzymes CYP1A1, CYP3A and CYP2S1 also
contributed to the 4-hydroxylation of AtRA [22,23], but the
expression of these enzymes was not detectable in either mock-
treated or AtRA-treated T cells (data not shown). Even at a
concentration as low as 1 nM, AtRA induced moderate but
significant expression of Cyp26b1 (Fig. 2B). In the presence of
10 nM AtRA, Cyp26b1 expression became detectable after 48 h of
stimulation of naı ¨ve CD4
+ T cells with antibodies to CD3 and
CD28. The cells were further cultured with AtRA and IL-2 but in
the absence of the antibodies for another 48 h to induce CCR9
expression. The Cyp26b1 expression reached a peak after 72 h and
decreased subsequently (Fig. 2C).
Inverse regulation of Ccr9 expression by altering
Cyp26b1 expression
We investigated whether Ccr9 expression can be affected by an
altered Cyp26b1 expression in T cells. The Ccr9 expression levels
induced in T cells transfected with the pCMV5 expression vector
containing the Cyp26b1 cDNA (Cyp26b1 expression vector) were
lower than those induced in T cells transfected with the pCMV5
vector alone (control vector) in the presence of 10 or 100 nM of
AtRA (Fig. 3A). We also analyzed the effect of RNA interference-
mediated silencing of Cyp26b1. In order to find out the optimal
transfection conditions for an efficient reduction of CYP26B1
expression, we first transfected COS7 cells with either control
short interfering RNA (siRNA) or Cyp26b1 siRNA together with
the expression vector encoding a CYP26B1-green fluorescent
protein (GFP) fusion protein (pAcGFP-Cyp26b1), and analyzed
their protein levels by Western blot using anti-GFP antibody.
Compared with the control siRNA transfection, the Cyp26b1
siRNA transfection dramatically reduced the CYP26B1-GFP
expression levels (Fig. 3B). Depending on the results, we next
transfected CD4
+ T cells with 100 nM Cyp26b1 siRNA, and
assessed its effect on the Ccr9 expression. Real-time PCR analysis
revealed that AtRA-induced Ccr9 expression levels were signifi-
cantly higher in T cells treated with Cyp26b1 siRNA than those
treated with control siRNA (Fig. 3C). These results suggest that
AtRA-induced Ccr9 expression is inversely regulated by Cyp26b1
expression.
A CYP26 inhibitor upregulates RA-induced CCR9
expression
Liarozole is a standard inhibitor of CYP26 [24]. Liarozole
significantly enhanced AtRA-induced CCR9 expression in T cells,
although the inhibitor alone slightly upregulated the basal levels
(Fig. 4A & 4B). The expression levels of Ccr9 mRNA induced by
10 or 100 nM AtRA were also enhanced by Liarozole (Fig. 4C).
The results indicate that CYP26B1 activity affects the AtRA-
induced expression of CCR9 on T cells.
Figure 1. Cyp26b1 is expressed in CD4
+ and CD8
+ T cells from
gut-related lymphoid organs. (A) Expression of Cyp26a1, Cyp26b1,
Cyp26c1 and Rplp0, a loading control, in CD4
+ or CD8
+ T cells from MLN,
Peyer’s patches (PP) or spleens (SPL) was analyzed by RT-PCR. (B)
Expression of Cyp26b1 in CD4
+CD44
2CD62L
high or CD4
+CD44
+ T cells
from MLN or peripheral lymph nodes (PLN) was analyzed by RT-PCR.
Data are shown as the mean 6 SD of triplicate cultures. Data are
representative of three independent experiments.
doi:10.1371/journal.pone.0016089.g001
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It is known that RA directly and indirectly modulates functional
differentiation of naı ¨ve T cells [25–28]. As cytokines play critical
roles in functional differentiation of naı ¨ve CD4
+ T cells, we
examined if cytokines might affect Cyp26b1 expression in T cells
upon activation. None of the cytokines we examined could induce
Figure 2. RA induces Cyp26b1 expression in T cells. (A) Naı ¨ve
CD4
+ T cells were stimulated with antibodies to CD3 and CD28 in the
presence or absence of AtRA (10 or 100 nM) for 2 days, and were
further cultured with IL-2 and the same concentration without
antibodies for 2 days. The cells were analyzed for the Cyp26 expression
by RT-PCR. Rplp0 was used as a loading control. (B) Naı ¨ve CD4
+ T cells
were cultured as above but in the presence of graded concentrations of
AtRA (0–100 nM). The mRNA levels were measured by quantitative real-
time PCR. The expression levels are indicated as ‘fold induction’ relative
to the level in the control cells without AtRA. (C) Naı ¨ve CD4
+ T cells were
cultured as above in the presence (squares) or absence (rhombuses) of
10 nM AtRA, and aliquots of the cells were harvested at 0, 6, 12, 24, 48,
72 and 96 h after the start of the culture. The mRNA levels were
measured by quantitative real-time PCR. The expression levels are
indicated as ‘fold induction’ relative to the level in the control cells
without AtRA at 0 h. (B, C) Data are shown as the mean 6 SD of
triplicate cultures. Data are representative of three independent
experiments.
doi:10.1371/journal.pone.0016089.g002
Figure 3. Inverse regulation of Ccr9 expression by altering
Cyp26b1 expression. (A) Naı ¨ve CD4
+ T cells were stimulated with
antibodies to CD3 and CD28 for 2 days, and were transfected with the
Cyp26b1 expression vector or the corresponding insertless plasmid
(Control vector). The cells were further stimulated with the antibodies
for 24 h, and were transferred and cultured in new wells containing IL-2
but without antibodies. AtRA (10 or 100 nM) or vehicle control was
added in all the cultures. The mRNA levels of Ccr9 were measured by
semi-quantitative real-time PCR. The expression levels are indicated as
‘fold induction’ relative to that in the control cells without AtRA. (B)
COS7 cells were transiently transfected with the GFP expression vector
(pAcGFP) or the CYP26B1-GFP fusion protein expression vector
(pAcGFP-Cyp26b1) together with graded amounts of Cyp26b1 siRNA
or control siRNA (33, 100 or 300 nM). The cells were analyzed for the
expression of CYP26B1-GFP protein and GFP protein by Western
blotting with anti-GFP antibody. (C) Naive CD4
+ T cells were stimulated
for 2 days, and were transfected with 100 nM of Cyp26b1 siRNA or
control siRNA. After the culture, mRNA levels of Ccr9 were measured by
semi-quantitative real-time PCR. Data are expressed as ‘fold induction’
of the levels detected in the control siRNA transfected cells in the
absence of AtRA. (A, C) Data are shown as the mean 6 SD of triplicate
cultures. Statistical significance was determined by the Student’s t-test;
**p , 0.01; *p , 0.05. Data are representative of three independent
experiments.
doi:10.1371/journal.pone.0016089.g003
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However, TGF-b1, TGF-b2 and IL-12 dramatically inhibited the
AtRA-induced Cyp26b1 expression, whereas IL-4 and TNF-a
significantly enhanced the expression (Fig. 5A & 5B). On the other
hand, IL-1b, IL-6, IL-10, IL-17A or IFN-c was of little effect on
the expression. It is known that the combination of RA and TGF-
b efficiently induces differentiation of naı ¨ve CD4
+ T cells into
Foxp3
+ iTreg [6–11]. Thus, during the differentiation into Foxp3
+
iTreg, TGF-b might protect RA-dependent signals by inhibiting
the CYP26B1 expression. In fact, TGF-b significantly enhanced
the RA-induced CCR9 expression on T cells (Fig. 5C & 5D).
Meanwhile, RA significantly enhanced Foxp3 expression on T
cells as reported [6–11].
Discussion
In the present study, we found that Cyp26b1 is expressed in
antigen-experienced T cells from gut-related lymphoid organs,
and that RA induced Cyp26b1 expression in naı ¨ve T cells upon
activation (Fig. 1 & 2). Expression of the other Cyp26 family
members were not detected in T cells (Fig. 2A), although, in other
cell types, their expression can be also induced by RA [29–31].
The Cyp26b1 expression in T cells became detectable after 48 h of
culture in the presence of 10 nM AtRA (Fig. 2C). Previous studies,
however, showed that Cyp26a1 mRNA expression was induced
within 2 h of culture with AtRA in human keratinocyte-derived
HaCaT cells and within 3 h in NB4 and HL-60 cells [31,32].
These results suggest that the expression of Cyp26a1 is far more
rapidly induced than that of Cyp26b1. In the upstream region of
the Cyp26a1 gene in human and mouse, there are two typical
retinoic acid-response elements (RAREs) and a G-rich element.
These motifs appear to function synergistically to provide maximal
induction of Cyp26a1 in response to AtRA [33,34]. By contrast,
little is known about the regulatory mechanisms of the Cyp26b1
gene expression, and thus far no functional RARE has been
reported. More than 500 genes have been suggested to be
regulatory targets of AtRA, and approx. 75% of these genes are
likely to be regulated indirectly [35,36]. Considering the lack of an
apparent RARE in the promoter region of the Cyp26b1 gene and
its delayed expression, the expression of Cyp26b1 is likely to be
regulated indirectly by RA.
It was reported that constitutive expression of Cyp26a1 cDNA in
P19 and HeLa cells made them hyposensitive to RA [15]. On the
contrary, the CYP26 inhibitor ketoconazole enhanced AtRA-
dependent reporter gene expression in HaCaT cells [32].
CYP26A1 and CYP26B1 exhibit a high degree of specificity for
AtRA, while CYP26C1 can catabolize both AtRA and 9-cis-RA
[30,37,38]. Therefore, the intracellular availability of AtRA and
the AtRA-dependent gene expression can be controlled by the
expression and activity of CYP26 enzymes. Our present results
suggest that AtRA-induced Ccr9 expression in T cells is influenced
by the expression and activity of CYP26B1 (Fig. 3 & 4). CYP26B1
may thus affect the tissue homing specificity of T cells.
IL-4 and IL-12 affected the AtRA-induced expression of
Cyp26b1 (Fig. 5A). We have previously shown that AtRA directly
suppresses IL-12-dependent differentiation of naı ¨ve CD4
+ T cells
to Th1 cells, and enhances or suppresses IL-4-dependent
differentiation to Th2 cells depending on its concentration and
Figure 4. The CYP26 inibitor, Liarozole, upregulates RA-induced CCR9 expression. Naı ¨ve CD4
+ T cells were cultured as described in the
legend of Fig. 2A but in the presence or absence of Liarozole (50 mM) with or without AtRA (10 nM) (A) or with graded concentrations of AtRA (B). The
cells were analyzed for the surface expression of CCR9 by flow cytometry. (C) Naı ¨ve CD4
+ T cells were cultured as above in the presence or absence of
Liarozole (25 or 50 mM) with or without AtRA (10 or 100 nM). Ccr9 mRNA levels were measured by semi-quantitative real-time PCR assay. The expression
levels areindicated as ‘fold induction’ relative to the level in the control cellswithout AtRA. (B, C) Data areshownas the mean 6 SD of triplicate cultures.
Statistical significance was determined by the Student’s t-test; *p , 0.05. Data are representative of three independent experiments.
doi:10.1371/journal.pone.0016089.g004
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the RA-dependent suppression of Th1 differentiation, but may
modulate the RA effect on Th2 differentiation in the RA-rich
microenvironment like in the small intestinal tissue. We also found
that TGF-b markedly inhibited AtRA-induced expression of
Cyp26b1 (Fig. 5A & 5B). It has long been known that cross-talk
between RA and TGF-b is crucial in embryonic development.
Retinoid imbalance affects TGF-b expression in embryo, and
causes teratogenic effects [39,40]. TGF-b is known to suppress the
expression of RA receptors and a cytoplasmic RA-binding protein
in embryonic cells [41,42]. Cross-talk between RA and TGF-b
also plays important roles in functional differentiation of T cells.
We found that TGF-b significantly enhanced AtRA-induced
CCR9 expression (Fig. 5C & D). On the other hand, AtRA
enhanced TGF-b-induced Foxp3 expression on T cells as
previously reported [6–11] (Fig. 5C & D). RA signals that enhance
Figure 5. TGF-b inhibits RA-induced Cyp26b1 expression. (A, B) Naı ¨ve CD4
+ T cells were cultured as described in the legend of Fig. 2A but in
the presence of various cytokines (10 ng/ml each) with AtRA (10 nM) (A), or graded concentrations of AtRA together with 4 ng/ml of TGF-b1o r
10 ng/ml of TNF-a (B). The expression of Cyp26b1 was assessed by semi-quantitative real-time PCR. The expression level is indicated as ‘fold
induction’ relative to the expression level in the AtRA-treated cells without cytokine (A), or the expression level in the control cells in the absenceo f
AtRA (B). Data are shown as the mean 6 SD of quadruplicate cultures (A) or triplicate cultures (B). Statistical significance was determined by the
Student’s t-test; ***p , 0.001; **p , 0.01; *p , 0.05, Cytokine-treated vs. Control for (A) or as indicated in the panel (B). (C, D) CD4
+CD44
2 T cells were
cultured in the presence of AtRA (10 nM), TGF-b1 (4 ng/ml) or the combination of them for 4 days. The cells were analyzed for the expression of
Foxp3 and CCR9 by flow cytometry. (C) Data are shown as the mean 6 SD of triplicate cultures. Statistical significance was determined by the
Student’s t-test; ***p , 0.001. (D) Representative flow-cytometric profiles are shown. Data are representative of three independent experiments.
doi:10.1371/journal.pone.0016089.g005
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+ iTreg and their
acquisition of gut-homing specificity were unlikely to be
suppressed by CYP26B1. Aberrant expression of CYP26B1 may
disturb not only the tissue homing specificity but also the
differentiation into iTreg. On the other hand, TNF-a enhanced
RA-induced expression of Cyp26b1 (Fig. 5B). As TNF-a contrib-
utes to inflammatory responses through diverse biological actions,
T cells activated in the presence of TNF-a may actively diminish
RA signals that induce immunosuppression and/or homing into
uninflamed gut tissues.
Inflammatory bowel diseases (IBD) represent chronic relapsing
and remitting inflammatory disorders of the gastrointestinal tract,
and are characterized by leukocytic infiltration of the intestinal
mucosa. In peripheral blood lymphocytes, CCR9-positive T cells
were markedly elevated in patients with Crohn’s disease [43]. It
was also shown that the percentage of CCR9-positive lymphocytes
increased in murine model of Crohn’s disease, and neutralization
of the receptor or the chemokine attenuated early disease [44].
These CCR9-positive lymphocytes might be mainly pro-inflam-
matory but not anti-inflammatory, as the balance between
regulatory T cells and Th17 may affect the disease outcome
[45]. It is becoming likely that RA-signal levels in the gut largely
affect the IBD development. The regulation of retinoid metabo-
lism may offer novel therapeutic strategies for treatment of IBD.
Materials and Methods
Ethics statement
All animal experiments were performed according to the
protocols approved by the Animal Care and Use Committee of
Tokushima Bunri University (protocol # KP09-41-001).
Mice
B10.D2 mice and TCR-DO11.10/Rag2
2/2 (B10.D2/AiTac-
TgN(DO11.10)-Rag2
tm1) mice were from Japan SLC (Hamamatsu,
Japan) and Taconic Farm (Hudson, USA), respectively. All animals
were maintained in the specific pathogen free condition in the
animal facility of Tokushima Bunri University at Kagawa Campus.
Isolation of lymphocytes from secondary lymphoid
tissues
Single cell suspensions were prepared from MLN, Peyer’s patches,
PLN and spleens of B10.D2 mice. For isolation of CD4
+ T cells,
CD4
+ T cells were positively isolated using DynabeadsH Mouse CD4
(Invitrogen, Carlsbad, USA). For isolation of CD8
+ Tc e l l s ,C D 8
+ T
cells were stained with phycoerythrin (PE)-conjugated anti-CD8a
antibody (BD Biosciences, Franklin Lakes, USA) and positively
isolated using anti-PE antibody-coupled magnetic cell-sorting
microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany). Purified
CD4
+ and CD8
+ T cells were immediately used for the RNA
extraction. Naı ¨ve CD4
+CD62L
high T cellswerepurified as previously
described [1,46]. For sorting of effector/memory CD4
+ T cells, cells
were purified using EasysepH mouse CD4
+ T cell enrichment kit
(Stemcell, Vancouver, Canada), and were stained with PE-Cy7
TM
-
conjugated anti-CD4 (BioLegend, San Diego, USA), fluorescein
isothiocyanate (FITC)-conjugated anti-CD62L (BD Biosciences) and
allophycocyanin (APC)-conjugated anti-CD44 (BioLegend) antibod-
ies. CD4
+CD44
+ and CD4
+CD44
2CD62L
high cells were sorted on a
BD FACSAria
TM
(BD Biosciences), to .95% purity.
Naı ¨ve T cell culture
Naı ¨ve CD4
+ T cells were cultured as previously described with a
slight modification [1,46]. Briefly, the cells were added into the
plates coated with 5 mg/ml of anti-CD3 (145-3C11) and 1 mg/ml
of anti-CD28 (BioLegend) antibodies, and cultured for 2 days in
the presence of AtRA. The cells were then transferred into the
medium containing 20 units/ml of IL-2 and AtRA, and cultured
for another 2 days. In some experiments, cytokines (Peprotech,
Rocky Hill, USA) or Liarozole (Tocris Bioscience, Ellisville, USA)
was added to the culture. For the induction of Foxp3
+ T cells,
CD4
+CD44
2 T cells from spleen and MLN of B10.D2 mice were
isolated by negative selection using an EasySepH Mouse CD4
+ T
cell enrichment kit supplemented with biotinylated anti-CD44
antibody (BioLegend). The cells were added into the plates coated
with 5 mg/ml of anti-CD3 and 1 mg/ml of anti-CD28 antibodies,
and cultured for 2 days in the presence of 10 nM of AtRA, 4 ng/
ml of TGF-b1 or the combination of the two. The cells were then
transferred into the medium containing 1.25 units/ml of IL-2 with
or without AtRA and TGF-b1, and cultured for another 2 days.
Transfection of COS7 cells
The cDNA sequence of Cyp26b1 containing the entire open
reading frame was amplified by PCR and cloned into pAcGFP1-
N1 (BD Biosciences). The siRNA cocktail targeting the mouse
Cyp26b1 was purchased from B-Bridge international Inc. (Cuper-
tino, USA), which contains 3 siRNAs (Table S1). The control
siRNA cocktail was also purchased from B-Bridge International
Inc. (catalog number S6C-0126). COS7 cells were transfected with
the expression vector with or without the cDNA together with
siTrio Cyp26b1 siRNA or siTrio negative control siRNA using
Lipofectamine
TM 2000 reagent (Invitrogen). The transfected cells
were lysed at 48 h post-transfection.
Immunoblot analysis
A.v. Peptide Antibody (Clontech, Mountain View, USA) was
used to detect GFP-fused proteins. Cells were lysed for 30 min on
ice in 1% (v/v) Triton X-100, 150 mM NaCl, 20 mM Tris-HCl,
1 mM EDTA and 1% (v/v) protease inhibitor cocktail (Nacalai
tesque, Kyoto, Japan), and cell lysates were centrifuged at
20,0006g for 5 min. Proteins in cell lysates were separated by
SDS-PAGE, and were transferred to nitrocellulose membranes
(GE Healthcare, Little Chalfont, UK). The membranes were
probed with A.v. Peptide Antibody followed by incubation with
horseradish peroxidase-conjugated goat anti-rabbit IgG Ab
(Zymed Laboratories, South San Francisco, USA) and were
developed by ECL
TM
Western Blotting Detection Reagents (GE
Healthcare), and bands were visualized by a LAS-3000 (Fujifilm,
Tokyo, Japan).
Transfection of CD4
+ T cells
Transfection of CD4
+ T cells was performed by electroporation
using Mouse T Cell Nucleofector Kit (Amaxa, Gaithersburg,
USA). Naı ¨ve CD4
+ T cells were stimulated with plate-bound
antibodies to CD3 and CD28 as described above. After 2 days of
stimulation, T cells (1610
6 cells) were transfected with 4 mg of the
Cyp26b1 expression vector (pCMV5-Cyp26b1) or the correspond-
ing insertless plasmid (pCMV5). After electroporation, the cells
were re-stimulated for 1 day with plate-bound antibodies to CD3
and CD28. The cells were then transferred into the medium
containing 20 units/ml of IL-2 with or without AtRA, and
cultured for another 2 days. For the siRNA knocking down study,
naı ¨ve CD4
+ T cells were stimulated with anti-CD3 and anti-CD28
antibodies coated on the plates described as above. After 2 days of
stimulation, T cells (1610
6 cells) were transfected with 100 nM of
siTrio Cyp26b1 siRNA or siTrio negative control cocktail. After
electroporation, the cells were re-stimulated for 1 day with or
without AtRA with anti-CD3 and anti-CD28 antibodies coated on
the plates as described above. The cells were then expanded in the
Retinoic Acid Metabolism and Signaling in T Cells
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another 2 days.
Real-time PCR
Real-time PCR was performed as previously described with a
slight modification [46]. Total RNA was isolated from cells using
RNeasyH Mini Kit (Qiagen, Hilden, Germany), and cDNA was
generated using QuantiTectH Reverse Transcription Kit (Qiagen).
cDNA was used as a template for real-time PCR with Power
SYBRH Green Master Mix (Applied Biosystems, Foster City,
USA) and gene-specific primers (Table S2). The reaction was
performed with Applied Biosystems 7500 real time PCR system
(Applied Biosystems). Analysis was performed with Applied
Biosystems 7500 real time PCR system or fractionation in a 2%
(w/v) agarose/TAE gel. Real-time PCR conditions consisted of an
initial denaturing step at 50uC for 2 min and 95uC for 10 min,
followed by 40 cycles of denaturation for 15 s at 95uC, annealing
and extension for 1 min at 60uC. All reactions were performed in
triplicates.
Fluorescence-activated cell-sorting (FACS) analysis
The cells were stained with APC-conjugated anti-CD4
(BioLegend) and PE-conjugated anti-CCR9 (R&D Systems,
Minneapolis, USA) antibodies in the presence of anti-FcR
antibody, and were analyzed with a BD FACSCalibur
TM
instrument and the BD CellQuest
TM Pro software (BD Bioscienc-
es). Intracellular staining of Foxp3 was performed using APC
mouse/rat Foxp3 staining set (eBioscience, San Diego, USA).
Supporting Information
Table S1 Sequences of siRNAs using knocking down the
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